KR20070045187A - 항암제의 효과 증강제 - Google Patents

항암제의 효과 증강제 Download PDF

Info

Publication number
KR20070045187A
KR20070045187A KR1020077000537A KR20077000537A KR20070045187A KR 20070045187 A KR20070045187 A KR 20070045187A KR 1020077000537 A KR1020077000537 A KR 1020077000537A KR 20077000537 A KR20077000537 A KR 20077000537A KR 20070045187 A KR20070045187 A KR 20070045187A
Authority
KR
South Korea
Prior art keywords
cancer
chemotherapy
patients
donor
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020077000537A
Other languages
English (en)
Korean (ko)
Inventor
히로야스 야스다
무쓰오 야마야
가쓰토시 나카야마
히데타다 사사키
Original Assignee
고쿠리츠다이가쿠호진 도호쿠다이가쿠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고쿠리츠다이가쿠호진 도호쿠다이가쿠 filed Critical 고쿠리츠다이가쿠호진 도호쿠다이가쿠
Publication of KR20070045187A publication Critical patent/KR20070045187A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020077000537A 2004-06-10 2005-06-10 항암제의 효과 증강제 Abandoned KR20070045187A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JPJP-P-2004-00173174 2004-06-10
JP2004173174 2004-06-10

Publications (1)

Publication Number Publication Date
KR20070045187A true KR20070045187A (ko) 2007-05-02

Family

ID=34970391

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077000537A Abandoned KR20070045187A (ko) 2004-06-10 2005-06-10 항암제의 효과 증강제

Country Status (8)

Country Link
US (2) US20080039521A1 (https=)
EP (1) EP1778215B1 (https=)
JP (2) JP4729503B2 (https=)
KR (1) KR20070045187A (https=)
CN (1) CN101001623B (https=)
DE (1) DE602005018222D1 (https=)
ES (1) ES2338022T3 (https=)
WO (1) WO2005120493A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888510A4 (en) 2005-05-27 2013-01-16 Univ North Carolina NITROGEN OXIDE-RELATED PARTICLES FOR NITROGEN OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS
JP2010024170A (ja) * 2008-07-17 2010-02-04 Hiroshi Maeda 抗悪性腫瘍剤の腫瘍組織への局所送達増強剤
WO2010044875A2 (en) * 2008-10-16 2010-04-22 Novan, Inc. Nitric oxide releasing particles for oral care applications
US8731840B2 (en) * 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072799B2 (en) * 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060926B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8793075B2 (en) * 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072688B2 (en) * 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050070B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060934B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8613937B2 (en) * 2008-10-31 2013-12-24 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8762067B2 (en) * 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US20100111834A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US20100111831A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for surface abrasion with frozen particles
US8603494B2 (en) * 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8731841B2 (en) * 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111857A1 (en) * 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US9050251B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8858912B2 (en) * 2008-10-31 2014-10-14 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US9050317B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US20100111836A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US8725420B2 (en) * 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100111841A1 (en) * 2008-10-31 2010-05-06 Searete Llc Compositions and methods for surface abrasion with frozen particles
US8721583B2 (en) * 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8414356B2 (en) * 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US9060931B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US20100111835A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US8603495B2 (en) * 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
WO2011047013A1 (en) * 2009-10-13 2011-04-21 Novan, Inc. Nitric oxide-releasing coatings
CN102107009A (zh) * 2009-12-25 2011-06-29 奇复康药物研发(苏州)有限公司 天然药物组分和一氧化氮供体的混合复方药物及其用途
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
ES2695173T3 (es) 2011-02-28 2019-01-02 Novan Inc Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas
JP5842367B2 (ja) * 2011-04-07 2016-01-13 ニプロ株式会社 抗癌剤増感剤
US20140088034A1 (en) * 2011-05-11 2014-03-27 Stc.Unm NITRIC OXIDE/cGMP PATHWAY INHIBITION OF VLA-4 RELATED CELL ADHESION
CN103130815B (zh) * 2013-02-07 2015-10-07 浙江工业大学 一种单硝酸异山梨酯衍生物及其制备方法和应用
EP3108890B1 (en) 2014-02-20 2022-12-28 Hirofumi Yamamoto Enhancer of anti-tumor effect of anti-cancer agent
US10214743B2 (en) 2014-03-04 2019-02-26 Hirofumi Yamamoto Colorectal cancer drug, and method for predicting prognosis of colorectal cancer patient
WO2016015095A1 (en) * 2014-07-31 2016-02-04 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
CN107823644B (zh) * 2017-11-07 2021-03-02 福州大学 一种no供体化合物在制备抑制富含巯基分子的肿瘤细胞的侵袭和转移能力药物中的应用
CN109498818B (zh) * 2018-05-25 2021-08-31 福州大学 一种产生NO的pH敏感脂质体及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173738A1 (en) * 1993-10-08 1995-04-20 James B. Mitchell Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers
EP0888458A4 (en) * 1996-02-20 2004-05-06 Sloan Kettering Institutefor C COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER
IT1282686B1 (it) * 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
WO2001054680A2 (en) 2000-01-26 2001-08-02 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20020173538A1 (en) * 2000-06-30 2002-11-21 Ming-Shi Shiao Method for sensitizing cancer cells to cancer therapies with a mevalonate-reducing compound
JP2005527510A (ja) * 2002-03-06 2005-09-15 セレジー ファーマシューティカルズ インコーポレーティッド 癌の治療において一酸化窒素模倣体を使用するための製剤および方法

Also Published As

Publication number Publication date
CN101001623A (zh) 2007-07-18
US8410175B2 (en) 2013-04-02
JP4729503B2 (ja) 2011-07-20
JP2011144190A (ja) 2011-07-28
ES2338022T3 (es) 2010-05-03
EP1778215B1 (en) 2009-12-09
DE602005018222D1 (https=) 2010-01-21
EP1778215A1 (en) 2007-05-02
WO2005120493A1 (en) 2005-12-22
CN101001623B (zh) 2010-11-17
US20090137683A1 (en) 2009-05-28
US20080039521A1 (en) 2008-02-14
WO2005120493A8 (en) 2007-03-22
JP2008501630A (ja) 2008-01-24

Similar Documents

Publication Publication Date Title
KR20070045187A (ko) 항암제의 효과 증강제
JP2008501630A6 (ja) 抗癌剤の効果増強剤
Pauwels et al. Combined modality therapy of gemcitabine and radiation
Lee et al. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study
NO333972B1 (no) Kombinasjoner av epotilonanaloger og kjemoterapeutiske midler for behandling av proliferative sykdommer
Filis et al. Breakthrough in RAS targeting with pan-RAS (ON) inhibitors RMC-7977 and RMC-6236
Kaira et al. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer
JP2018177808A (ja) 抗癌療法
Rudno-Rudzińska et al. New therapeutic strategy: Personalization of pancreatic cancer treatment-irreversible electroporation (IRE), electrochemotherapy (ECT) and calcium electroporation (CaEP)–A pilot preclinical study
Pershing et al. Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer
Mason et al. Biology-based combined-modality radiotherapy: workshop report
Poggi et al. Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer
EP3445347B1 (en) Chemotherapy improvements with idronoxil
Celio et al. Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study
Meyer et al. A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer
Fracasso et al. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study
William Jr et al. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer
US11890292B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
Jeremić et al. Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients
KR20170079128A (ko) PPAR-β 길항제를 포함하는 항암 효과 증진용 약학적 조성물
Leighl et al. A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium
Yip et al. A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies
Messersmith et al. 588 A first-in-patient phase I study of the novel gamma secretase inhibitor PF-03084014 in patients with advanced solid tumor malignancies
Edelman et al. Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer
JP2014513698A (ja) がん治療保護のためのヒ素の使用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070109

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20070604

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100427

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20111125

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20120823

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee